These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640 [TBL] [Abstract][Full Text] [Related]
23. Effect of atorvastatin and pravastatin on serum C-reactive protein. Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Taylor AJ Am Heart J; 2003 Feb; 145(2):e8. PubMed ID: 12595863 [TBL] [Abstract][Full Text] [Related]
24. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299 [TBL] [Abstract][Full Text] [Related]
25. Increased expression of Gi-coupled muscarinic acetylcholine receptor and Gi in atrium of elderly diabetic subjects. Richardson MD; Kilts JD; Kwatra MM Diabetes; 2004 Sep; 53(9):2392-6. PubMed ID: 15331550 [TBL] [Abstract][Full Text] [Related]
26. Statins and C-reactive protein. Kluft C; de Maat MP; Gevers Leuven JA; Potter van Loon BJ; Mohrschladt MF Lancet; 1999 Apr; 353(9160):1274. PubMed ID: 10217112 [No Abstract] [Full Text] [Related]
27. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Jackevicius CA; Anderson GM; Leiter L; Tu JV Arch Intern Med; 2001 Jan; 161(2):183-8. PubMed ID: 11176731 [TBL] [Abstract][Full Text] [Related]
28. Go but not Gi2 or Gi3 is required for muscarinic regulation of heart rate and heart rate variability in mice. Duan SZ; Christe M; Milstone DS; Mortensen RM Biochem Biophys Res Commun; 2007 May; 357(1):139-43. PubMed ID: 17418106 [TBL] [Abstract][Full Text] [Related]
29. Increased inducibility of ventricular tachycardia and decreased heart rate variability in a mouse model for type 1 diabetes: effect of pravastatin. Rajab M; Jin H; Welzig CM; Albano A; Aronovitz M; Zhang Y; Park HJ; Link MS; Noujaim SF; Galper JB Am J Physiol Heart Circ Physiol; 2013 Dec; 305(12):H1807-16. PubMed ID: 24163078 [TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering drugs and homocysteine. de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885 [No Abstract] [Full Text] [Related]
31. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Flapan AD; Nolan J; Neilson JM; Ewing DJ Am J Cardiol; 1992 Feb; 69(5):532-5. PubMed ID: 1736619 [TBL] [Abstract][Full Text] [Related]
32. [Dyslipidemia in diabetes mellitus: statins treatment raises survival of patients]. Shestakova MV Ter Arkh; 1999; 71(1):67-9. PubMed ID: 10097307 [No Abstract] [Full Text] [Related]
33. Early experience with pravastatin in South African patients with type II hyperlipidaemia. Steingo L; Altona B; Anderson GW; Benkenstein TM; Bennett JM; Bhoola RL; Blake TA; Blomerus P; Botha AP; Branken TI S Afr Med J; 1992 Dec; 82(6):488. PubMed ID: 1465711 [No Abstract] [Full Text] [Related]
34. The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. Schooneveldt YL; Giles C; Keating MF; Mellett NA; Jurrjens AW; Paul S; Calkin AC; Meikle PJ Metabolites; 2021 May; 11(6):. PubMed ID: 34070445 [TBL] [Abstract][Full Text] [Related]
35. Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Fan YM; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Knuuti J; Lehtimäki T Clin Genet; 2001 Oct; 60(4):319-21. PubMed ID: 11683781 [No Abstract] [Full Text] [Related]
36. [Preservation of level of parasympathetic effect on human heart under conditions of acute hypoxia as an index of high hypoxic resistance. Wavelet-analysis]. Nesterov SV; Nesterov VP Zh Evol Biokhim Fiziol; 2007; 43(1):101-3. PubMed ID: 17408099 [No Abstract] [Full Text] [Related]
37. Visit-to-visit lipid variability: Clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics. Smit RAJ; Jukema JW; Postmus I; Ford I; Slagboom PE; Heijmans BT; Le Cessie S; Trompet S J Clin Lipidol; 2018; 12(2):266-276.e3. PubMed ID: 29422286 [TBL] [Abstract][Full Text] [Related]
38. Improvement in sleep apnoea associated with switch from simvastatin to pravastatin. Cham S; Gill K; Koperski S; Golomb BA BMJ Case Rep; 2009; 2009():. PubMed ID: 21886657 [TBL] [Abstract][Full Text] [Related]